JR-141
Phase 3- Indications
- Mucopolysaccharidosis II
Company intelligence / Profile preview
ArmaGen
San Diego, California, United States
- Ownership
- Private
- Employees
- ~15
- Development stage
- Phase 3
01
Overview
ArmaGen has developed a proprietary technology that enables therapies to cross the blood-brain barrier. Their lead candidate SHP-631 (formerly AGT-182) for Hunter syndrome reached Phase 2 clinical trials. The company achieved a clinical milestone in 2015 with dosing patients in its Phase 1 trial of AGT-182.
- Therapeutic areas
- OncologyRare DiseasesNeurology
- Modalities
- Fusion proteinEnzyme replacement therapy
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Shire plc
Beyond the preview
Go deeper on ArmaGen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ArmaGen.